Literature DB >> 26500294

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Kush Dalal, Mani Roshan-Moniri, Aishwariya Sharma, Huifang Li, Fuqiang Ban, Mohamed D Hassona, Michael Hsing, Kriti Singh, Eric LeBlanc, Scott Dehm, Emma S Tomlinson Guns, Artem Cherkasov, Paul S Rennie.   

Abstract

Entities:  

Year:  2015        PMID： 26500294      PMCID： PMC4646241          DOI： 10.1074/jbc.A115.553818

Source DB:  PubMed          Journal:  J Biol Chem        ISSN： 0021-9258            Impact factor:   5.157


× No keyword cloud information.
  3 in total

1.  Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone.

Authors:  Khalid Z Masoodi; Kurtis Eisermann; Zhenyu Yang; Javid A Dar; Laura E Pascal; Minh Nguyen; Katherine O'Malley; Erica Parrinello; Firuz G Feturi; Alex N Kenefake; Joel B Nelson; Paul A Johnston; Peter Wipf; Zhou Wang
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

2.  Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression.

Authors:  Jingbo Qiao; Magdalena M Grabowska; Ingrid S Forestier-Roman; Janni Mirosevich; Thomas C Case; Dai H Chung; Justin M M Cates; Robert J Matusik; H Charles Manning; Renjie Jin
Journal:  Oncotarget       Date:  2016-09-20

3.  Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer.

Authors:  Mona Kafka; Fabian Mayr; Veronika Temml; Gabriele Möller; Jerzy Adamski; Julia Höfer; Stefan Schwaiger; Isabel Heidegger; Barbara Matuszczak; Daniela Schuster; Helmut Klocker; Jasmin Bektic; Hermann Stuppner; Iris E Eder
Journal:  Cancers (Basel)       Date:  2020-07-28       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.